Racial diversity and reporting in United States Food and Drug Administration registration trials for thoracic malignancies from 2006-2020
File(s)
Accepted version
Author(s)
Type
Journal Article
Abstract
There is significant racial disparity in thoracic malignancies in terms of epidemiology and outcomes. We analyzed race reporting and racial diversity in the registration trials of drugs approved by the FDA for thoracic malignancies from 2006-2020. We found a significant under-representation of non-white participants in FDA drug registration trials in thoracic malignancies. Furthermore, though almost all trials report some race information, FDA guidelines are not universally followed. There is a disproportionate disease burden of lung cancer in under-represented race communities, and clinical trials should prioritize racial diversity and inclusion efforts.
Date Issued
2023
Date Acceptance
2022-09-29
Citation
Cancer Investigation, 2023, 41 (1), pp.43-47
ISSN
0735-7907
Publisher
Informa UK Limited
Start Page
43
End Page
47
Journal / Book Title
Cancer Investigation
Volume
41
Issue
1
Copyright Statement
© 2022 Taylor & Francis. This is an Accepted Manuscript of an article published by Taylor & Francis in Cancer Investigation on 05 Oct 2022 available online: https://doi.org/10.1080/07357907.2022.2131808
Identifier
https://www.tandfonline.com/doi/full/10.1080/07357907.2022.2131808
Publication Status
Published
Date Publish Online
2022-10-05